Literature DB >> 14595181

Implantable baclofen pump as an adjuvant in treatment of pressure sores.

Sarah A Mess1, Sylvia Kim, Steven Davison, Fred Heckler.   

Abstract

Currently, the success of ulcer treatment is limited by the high recurrence and complication rates. Spasticity is an important contributing factor to ulcer recurrence, and intrathecal baclofen is an effective method to reduce spasticity. Spasticity creates friction, shear, and mobility impairment resulting in wound dehiscence, flap loss, infection, and hematoma. Spasticity can be managed pharmacologically and surgically; baclofen is the drug of choice. Baclofen inhibits spasticity by blocking excitatory neurotransmitters in the spinal dorsal horn. Intrathecal baclofen maximizes the dose delivered to spinal receptors and minimizes the side effects associated with oral baclofen. Case reports of intrathecal baclofen used in patients with pressure sores demonstrate the use of intrathecal baclofen to improve reconstructive outcomes in spastic patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595181     DOI: 10.1097/01.SAP.0000070645.30682.93

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  4 in total

1.  Pressure sores with associated spasticity: a clinical challenge.

Authors:  Bishara S Atiyeh; Shady N Hayek
Journal:  Int Wound J       Date:  2005-03       Impact factor: 3.315

2.  Cohort study of atypical pressure ulcers development.

Authors:  Efraim Jaul
Journal:  Int Wound J       Date:  2013-02-04       Impact factor: 3.315

3.  Baclofen pump pocket infection: a case report of successful salvage with muscle flap.

Authors:  Bishara S Atiyeh; Shady N Hayek; Ghassan S Skaf; Ali Al Araj; Roukoz B Chamoun
Journal:  Int Wound J       Date:  2006-03       Impact factor: 3.315

Review 4.  Management of spasticity in children with cerebral palsy.

Authors:  Alireza Shamsoddini; Susan Amirsalari; Mohammad-Taghi Hollisaz; Alireza Rahimnia; Amideddin Khatibi-Aghda
Journal:  Iran J Pediatr       Date:  2014-05-09       Impact factor: 0.364

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.